Praxis Precision Medicines, Inc. Stock Price, News & Analysis

Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation in two upcoming investor conferences. The first is the Citi Biotech Virtual Co-Panel Day on May 18, 2022, featuring panels on 'Mood Disorders/Mental Health' at 11:00 a.m. ET and 'Movement Disorders/Epilepsy' at 3:30 p.m. ET. The second is the H.C. Wainwright Global Investment Conference, where a company presentation will be available on May 24, 2022, at 7:00 a.m. ET. Webcasts of these events can be accessed on their website, with replays available for 90 days.

Praxis Precision Medicines (NASDAQ: PRAX) provided a corporate update on May 9, 2022, highlighting positive results from its Phase 2a study of PRAX-944 for essential tremor. The drug showed a 42% mean improvement in the Modified Activities of Daily Living score. The PRAX-114 Aria Study for Major Depressive Disorder is also complete, with topline results expected in June 2022. The company reported a cash balance of $222.5 million as of March 31, 2022, a decrease from $275.9 million, and a net loss of $68.7 million in Q1 2022.

PRAX-944 has shown promising results in the Phase 2a study for treating essential tremor (ET). A mean improvement of 42% in the Modified Activities of Daily Living score was observed by Day 42, with a significant distinction during the randomized withdrawal phase. The treatment was well-tolerated with no new safety findings. Following these results, Praxis intends to update the primary endpoint for the Phase 2b Essential1 study to focus on efficacy, indicating progress towards a potential treatment for ET patients.

Praxis Precision Medicines (NASDAQ: PRAX) announced participation in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 5:00 p.m. ET. The event will be accessible via live webcast on the company's website, with a replay available for 90 days post-event. Praxis focuses on developing therapies for central nervous system disorders linked to neuronal excitation-inhibition imbalance, leveraging genetic insights. The company has multiple clinical-stage product candidates addressing psychiatric and movement disorders, and epilepsy.

Praxis Precision Medicines (NASDAQ: PRAX) announced a corporate update and financial results for Q1 2022 set for May 9, 2022, post-market close. The management will share a video highlighting business and pipeline progress, followed by a live Q&A at 4:30 p.m. ET. Praxis is focused on developing therapies for CNS disorders linked to neuronal imbalances and boasts a broad portfolio, including multiple clinical-stage product candidates addressing various neurological and psychiatric disorders. For more, visit Praxis Medicines.

Praxis Precision Medicines hosted its 2022 Epilepsy Day in New York City, showcasing its advancements in treating CNS disorders. CEO Marcio Souza highlighted their innovative approaches and significant progress across three major epilepsy programs: PRAX-222, PRAX-562, and PRAX-628, all expected to reach clinical stages by the end of 2022. The company aims to address unmet needs in epilepsy management with targeted therapies. This event emphasized Praxis' multi-billion-dollar market opportunity in the epilepsy sector, reflecting its commitment to rapid drug development driven by genetic insights.

Praxis Precision Medicines (NASDAQ: PRAX) has announced an upcoming Epilepsy Day on April 27, 2022, from 8:30 a.m. to 11:30 a.m. ET, held virtually and in New York City. This event will highlight the company's extensive epilepsy pipeline, the largest in the industry, and discuss clinical and regulatory strategies. Key opinion leaders like Dr. Jacqueline French and Dr. Daniel Friedman will share insights on advancements in epilepsy and unmet patient needs. A live webcast will be available on their website, with a replay accessible for 90 days.

Praxis Precision Medicines (NASDAQ: PRAX) has announced that data from its PRAX-944 essential tremor (ET) program will be showcased at the 2022 American Academy of Neurology Annual Meeting in Seattle from April 2-7, and virtually from April 24-26. Chief Medical Officer Bernard Ravina highlighted the need for better therapeutic options for ET, as current treatments often have poor tolerability. PRAX-944, a T-type calcium channel blocker, has shown promise in reducing tremor symptoms with acceptable safety profiles. The oral presentation is scheduled for April 6 at 5:06 PM PT.

Praxis Precision Medicines (NASDAQ: PRAX) announced its participation in a fireside chat at Stifel’s 4th Annual CNS Day on March 29, 2022, at 11:30 a.m. ET. The event will be accessible through a live webcast on the company’s website, with a replay available for 90 days post-event. Praxis focuses on developing therapies for central nervous system disorders by leveraging genetic insights into neuronal excitation-inhibition imbalances, targeting both rare and prevalent neurological and psychiatric conditions. For more details, visit www.praxismedicines.com.